What is Syndax Pharmaceuticals Inc (SNDX) stock price today?

Syndax Pharmaceuticals Inc (SNDX) currently trades at $20.65 per share. The stock has a market capitalization of $1.69B and a P/E ratio of —x.

Is SNDX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Syndax Pharmaceuticals Inc has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Syndax Pharmaceuticals Inc's revenue and earnings?

Syndax Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $217.17M with profit margins of -112.00%. Earnings per share (EPS) is $-2.79.

SNDX

Syndax Pharmaceuticals Inc

NASDAQ: SNDX · HEALTHCARE · BIOTECHNOLOGY

$20.65

+2.74% today

Updated 2026-05-06

Market cap

$1.69B

P/E ratio

—

P/S ratio

7.79x

EPS (TTM)

$-2.79

Dividend yield

—

52W range

$9 – $26

Volume

1.6M

Market cap

$1.69B

P/E ratio

—

P/S ratio

7.79x

EPS (TTM)

$-2.79

Dividend yield

—

52W range

$9 – $26

Volume

1.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

7.3

Growth

B+

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →197 stocks currently score above 75

Price targets

Analyst target

$39.50

+91.28%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Revenue growth 223.60% QoQ

Risks

- Thin margins at -112.00%

- Negative free cash flow $-50.34M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$126.58M	$0.00	$23.68M	$172.35M	$217.17M
Net income	$-143.75M	$-209.36M	$-318.76M	$-285.42M	$-42.67M
EPS	—	—	—	—	$-2.79
Free cash flow	$-133.90M	$-160.60M	$-274.90M	$-323.17M	$-50.34M
Profit margin	-113.57%	—	-1,346.11%	-165.60%	-112.00%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SNDX	$1.69B	31	7.3	2.0	5.0	5.0	—	Avoid
LLY	$862.01B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$546.90B	59	4.7	9.0	3.3	6.0	-40.34%	Buy
ABBV	$365.43B	63	4.0	8.0	4.0	5.0	-22.55%	Buy
UNH	$336.72B	54	5.3	5.5	7.3	4.8	+43.12%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+3.99%	Buy

Smart narrative

Syndax Pharmaceuticals Inc trades at $20.65. Our Smart Value Score of 31/100 indicates the stock is weak. TTM revenue stands at $217.17M. with profit margins at -112.00%.

Frequently asked questions

What is Syndax Pharmaceuticals Inc's stock price?

Syndax Pharmaceuticals Inc (SNDX) trades at $20.65.

Is Syndax Pharmaceuticals Inc overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of Syndax Pharmaceuticals Inc (SNDX)?

The analyst target price is $39.50, representing +91.3% upside from the current price of $20.65.

What is Syndax Pharmaceuticals Inc's revenue?

TTM revenue is $217.17M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio7.79x

ROE-189.50%

Beta0.41

50D MA$22.91

200D MA$18.43

Shares out0.09B

Float0.08B

Short ratio—

Avg volume1.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

SNDX vs LLY →SNDX vs JNJ →SNDX vs ABBV →Stock screener →